Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00430638 · ClinicalTrials.gov registry record · Phase 4

A Study of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Stage I and Stage II Hypertension

A Phase 4 study of Hypertension, sponsored by Daiichi Sankyo.

Completed
Registry status
Phase 4
Development phase
278
Enrollment target
20
Study locations

NCT00430638 is a Phase 4 study of Hypertension that has completed, run by Daiichi Sankyo. The registered enrollment target is 278 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00430638, a Phase 4 study of Hypertension, has completed, sponsored by Daiichi Sankyo.

COMPLETED
Registry status
Phase 4
Development phase
278 participants
Enrollment target
20
Study locations

Study Summary

This 16 week study will examine the ability of olmesartan medoxomil to lower the blood pressure of patients with moderate to severe high blood pressure in comparison to placebo. The medication being tested has been approved by the FDA for the treatment of high blood pressure.

Conditions Studied

Hypertension

Interventions

  • DRUG Placebo
  • DRUG olmesartan medoxomil + hydrochlorothiazide, if necessary

Study Locations (20)

Florida

  • - Coral Gables
  • - Deerfield Beach
  • - DeLand
  • - Fort Lauderdale
  • - Hialeah
  • - Hollywood
  • - Pembroke Pines

Alabama

  • - Birmingham
  • - Mobile
  • - Muscle Shoals

California

  • - Carmichael
  • - Spring Valley

Arkansas

  • - Searcy

Illinois

  • - Chicago

New Jersey

  • - Elizabeth

North Carolina

  • - Winston-Salem

Ohio

  • - Cincinnati

Trial Details

FieldValue
Enrollment Target 278 participants
Start Date 2006-12
Est. Completion 2007-10
Phase Phase 4

Sponsor

Daiichi Sankyo

236 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00430638

The ClinicalTrials.gov registry entry for NCT00430638 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 278 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (92% lower). The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00430638 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Florida, Alabama, California.

Frequently Asked Questions

What is clinical trial NCT00430638 about?

NCT00430638 is a clinical study titled "A Study of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Stage I and Stage II Hypertension". This 16 week study will examine the ability of olmesartan medoxomil to lower the blood pressure of patients with moderate to severe high blood pressure in comparison to placebo. The medication being tested has been approved by the FDA for the treatment of high blood pressure.

What is the current status of trial NCT00430638?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 278 participants. The study started on 2006-12. Estimated completion is 2007-10.

What conditions does trial NCT00430638 study?

This clinical trial studies the following conditions: Hypertension.

What interventions are being tested in trial NCT00430638?

The interventions under investigation include: Placebo (DRUG), olmesartan medoxomil + hydrochlorothiazide, if necessary (DRUG).

Who is sponsoring clinical trial NCT00430638?

This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00430638 being conducted?

This trial has 20 study locations across Alabama, Arkansas, California, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hypertension

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.